Observational studyPLoS medicine2026
Multiview deep-learning-enabled histopathology for prognostic and therapeutic stratification in stage II colorectal cancer: A retrospective multicenter study.
Observational study in PLoS medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- V7-DiVA: a feature-based Deep MIL colorectal whole-slide histopathology research platform with blinded external image-input validation.Journal of translational medicine · 2026Article
- Spatial architecture of tertiary lymphoid structures represents an independent prognostic dimension in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- Annual Review of Systemic Medical Treatment for Colorectal Cancer in 2025.Cancer innovation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproximately 20% of patients with stage II colorectal cancer (CRC) experience tumor relapse despite standard surgical treatment. Histopathological analysis holds promise for postsurgical risk stratification and guiding adjuvant chemotherapy (ACT) decisions. The aim of this study was to use deep learning to extract explainable tissue biomarkers from whole-slide images. METHODS AND
findingsIn this retrospective cohort study, we developed and validated SurvFinder, an interpretable deep learning framework designed to autonomously identify tissue-based risk biomarkers from hematoxylin and eosin (H&E)-stained slides. The framework aims to support individualized risk stratification and explore associations with treatment outcomes. The present study included 6,950 H&E slides from 1,604 patients with stage II CRC across four independent cohorts in China. Patients were enrolled from 2012 to 2018 and followed for a minimum of 24 months. The primary outcome of the study was relapse-free survival (RFS). Our analyses identified tertiary lymphoid structures (TLSs) as critical prognostic features in stage II CRC. The multi-view integration of TLS characteristics by SurvFinder consistently demonstrated superior predictive and prognostic accuracy across four multicenter datasets (AUROC with 95% confidence interval [CI]: 0.827 [0.789,0.864], 0.805 [0.749,0.860], 0.805 [0.748,0.861], and 0.712 [0.621,0.804]), surpassing traditional clinical prognostic parameters (hazard ratio [HR]: 8.23, 95% CI: 5.43-12.47; p < 0.001). Using explainable AI (XAI) methods, we ensured model transparency and identified key TLS features-such as their location at the tumor periphery and their maturity state-as significant factors influencing prognosis and the efficacy of adjuvant therapy. The retrospective design without prospective validation and real-world clinical deployment is the main limitation of this study.
conclusionsTogether, these results highlight the potential utility of deep learning-based histopathological analysis for automated risk stratification in stage II CRC. In particular, our findings support the relevance of TLSs as a histological biomarker with potential implications for personalizing ACT decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.